Back to Screener

Prenetics Global Limited Class A Ordinary Share (PRE)

Price$17.94

Favorite Metrics

Price vs S&P 500 (26W)15.87%
Price vs S&P 500 (4W)-19.07%
Market Capitalization$298.70M

All Metrics

Book Value / Share (Quarterly)$15.43
P/TBV (Annual)1.71x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-30.56%
Cash Flow / Share (Quarterly)$1.07
Price vs S&P 500 (YTD)10.06%
Gross Margin (TTM)59.47%
Net Profit Margin (TTM)-76.91%
EPS (TTM)$-4.02
10-Day Avg Trading Volume0.14M
EPS Excl Extra (TTM)$-4.02
Revenue Growth (5Y)58.62%
EPS (Annual)$-4.15
ROI (Annual)-33.07%
Gross Margin (Annual)52.98%
Net Profit Margin (5Y Avg)-97.33%
Cash / Share (Quarterly)$5.43
Revenue Growth QoQ (YoY)-89.62%
ROA (Last FY)-28.66%
Revenue Growth TTM (YoY)-77.95%
EBITD / Share (TTM)$-3.78
ROE (5Y Avg)-35.49%
Operating Margin (TTM)-50.09%
Cash Flow / Share (Annual)$-6.85
P/B Ratio1.71x
P/B Ratio (Quarterly)1.27x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)7.34x
Net Interest Coverage (TTM)-29.45x
ROA (TTM)-29.05%
EPS Incl Extra (Annual)$-4.15
Current Ratio (Annual)3.01x
Quick Ratio (Quarterly)2.76x
3-Month Avg Trading Volume0.22M
52-Week Price Return378.44%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$11.48
P/S Ratio (Annual)3.23x
Asset Turnover (Annual)0.45x
52-Week High$23.63
Operating Margin (5Y Avg)-66.27%
EPS Excl Extra (Annual)$-4.15
CapEx CAGR (5Y)77.92%
26-Week Price Return19.85%
Quick Ratio (Annual)2.76x
13-Week Price Return12.13%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)3.01x
Enterprise Value$268.341
Revenue / Share Growth (5Y)39.53%
Asset Turnover (TTM)0.18x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)6.38x
Pretax Margin (Annual)-59.45%
Cash / Share (Annual)$5.43
3-Month Return Std Dev91.20%
Gross Margin (5Y Avg)44.02%
Net Income / Employee (TTM)$-0
ROE (Last FY)-33.40%
Net Interest Coverage (Annual)-29.43x
EPS Basic Excl Extra (Annual)$-4.15
Receivables Turnover (TTM)1.47x
EV / Free Cash Flow (TTM)33.75x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-4.02
Receivables Turnover (Annual)22.48x
ROI (TTM)-35.38%
P/S Ratio (TTM)8.17x
Pretax Margin (5Y Avg)-90.85%
Revenue / Share (Annual)$6.57
Tangible BV / Share (Annual)$11.48
Price vs S&P 500 (52W)348.61%
Year-to-Date Return12.70%
5-Day Price Return1.60%
EPS Normalized (Annual)$-4.15
ROA (5Y Avg)-50.65%
Net Profit Margin (Annual)-63.13%
Month-to-Date Return-8.13%
Cash Flow / Share (TTM)$-2.78
EBITD / Share (Annual)$-3.59
Operating Margin (Annual)-46.44%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)18.33x
ROI (5Y Avg)-34.31%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-4.02
P/TBV (Quarterly)1.71x
P/B Ratio (Annual)1.27x
Inventory Turnover (TTM)6.38x
Pretax Margin (TTM)-77.60%
Book Value / Share (Annual)$15.43
Price vs S&P 500 (13W)11.44%
Beta0.18x
P/FCF (Annual)36.56x
Revenue / Share (TTM)$2.28
ROE (TTM)-36.02%
52-Week Low$3.45

Analyst Recommendations

Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00

Industry Peers — Lab Analytical Instruments(22)

SymbolP/S Ratio (TTM)Revenue Growth (5Y)Gross Margin (TTM)Operating Margin (TTM)Price
PREPrenetics Global Limited Class A Ordinary Share
8.17x58.62%59.47%-50.09%$17.94
AAgilent Technologies Inc.
4.74x5.41%52.60%20.40%$118.25
WATWaters Corp
10.04x6.00%59.28%25.36%$319.04
MTDMettler-Toledo International
6.50x5.47%59.37%26.05%$1290.84
ILMNIllumina Inc
4.62x6.04%66.61%18.44%$132.72
RVTYRevvity, Inc.
3.64x-5.46%54.77%12.49%$89.53
BIOBio-Rad Laboratories, Inc.Class A
3.06x0.29%52.01%1.59%$291.09
BIO.BBio-Rad Laboratories, Inc. Class B
3.06x0.29%52.01%1.59%$277.00
BRKRPBruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A
1.75x11.57%47.13%1.40%$306.06
BRKRBruker Corporation
1.73x11.57%47.13%1.40%$38.94
AVTRAvantor, Inc.
0.86x0.49%32.65%-3.83%$8.26

About

Prenetics Global Ltd is a diversified health sciences company operating three consumer healthcare brands: IM8 (a fast-growing supplement brand), Europa (sports distribution in the USA), and CircleDNA (direct-to-consumer DNA testing). The company has established a Bitcoin treasury with an initial approximately $20 million investment and a board-approved comprehensive digital asset strategy, positioning itself at the intersection of healthcare innovation and digital assets.